List view / Grid view
22 October 2019 | By Halo Labs
Aqueous solubility of small molecule compounds is an essential parameter during the hit-to-lead stage of drug discovery as well as lead optimization and formulation. Low solubility can result in misleading ADMET/DMPK analyses if some fraction of a compound precipitates. Watch on-demand to find out more!
A new study, which has shown that the congenital heart condition LVNC could be be caused by signalling defects, may lead to potential therapies.
Cells containing Meflin play a role in restraining the progression of pancreatic cancer and could lead to new therapies against the disease.
Scientists in the US have identified a particular bacterial strain, Segmented filamentous bacteria (SFB), that can prevent and cure rotavirus in mice.
An unlimited breadth of user-upgradeable application modules expands your research capabilities and evolves with your research
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.
Almost all animal subjects exposed to genital herpes were protected by the novel vaccine.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.
Chronic inflammatory processes in ageing brains lead to lymphoma cells that have entered the brain tissue being retained.
New research findings suggest that gut microbiota may regulate lupus flares in pregnant women, presenting a therapeutic target.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
New lab on a chip technology has been developed to evaluate the effects of different drivers of NAFLD on liver cells.
